Timing of G-CSF for infection prevention in lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether giving a medicine called G-CSF early or later after chemotherapy helps prevent infections in people with non-Hodgkin's lymphoma. It may help keep your white blood cell counts healthy and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of non-Hodgkin's lymphoma and be scheduled for standard chemotherapy.
- You must be able to read and understand Thai.
- You must be able to attend follow-up visits after chemotherapy.
- You cannot be pregnant or breastfeeding.
- You cannot have serious heart, liver, or kidney disease, and you cannot have taken antibiotics in the week before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a drug called G-CSF affects certain immune cells and cancer stem cells in people with advanced lung cancer. The goal is to understand how these cells interact during chemotherapy and immunotherapy, which may help improve future treatments.
This trial looks at whether adding a medicine called G-CSF (which helps the body make more white blood cells) to antibiotics is better than antibiotics alone for children with cancer who develop a fever and low blood cell counts after chemotherapy.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Hear when a new Granulocyte Colony Stimulating Factor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.